|
BMT Research Updates |
04/01/2025 - 8:45am to 9:30am MDT |
|
CD19x22 CAR T cell therapy and severe ICANS: it’s been a bumpy ride |
04/08/2025 - 8:45am to 9:30am MDT |
|
BMT Quality Reporting: Clinical Chart Audit |
04/15/2025 - 8:45am to 9:30am MDT |
|
BMT/CT Quality Reporting: Occurrences- Apheresis, Laboratory, Clinical |
04/22/2025 - 8:45am to 9:30am MDT |
|
Establishing Multidisciplinary Frameworks for CMV Prevention and Treatment in High-Risk Posttransplant Patients |
04/29/2025 - 2:45am to 3:30am MDT |
|
Journal Club: If You Can’t Beat Them, Engineer Them: The Rise of the CD7 CAR-T |
05/06/2025 - 8:45am to 9:30am MDT |
|
GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity |
05/13/2025 - 8:45am to 9:30am MDT |
|
Verneris: High-Risk AML COG Paper |
05/27/2025 - 8:45am to 9:30am MDT |
|
BMT Quality Reporting: Clinical Annual Report |
06/03/2025 - 8:45am to 9:30am MDT |
|
BMT Quality Reporting: Apheresis, BMTL Annual Report |
06/10/2025 - 8:45am to 9:30am MDT |